Barclays PLC Buys 30,792 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Barclays PLC raised its position in Emergent BioSolutions Inc. (NYSE:EBS) by 361.6% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 39,308 shares of the biopharmaceutical company’s stock after buying an additional 30,792 shares during the period. Barclays PLC’s holdings in Emergent BioSolutions were worth $329,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its position in Emergent BioSolutions by 19.6% during the 3rd quarter. Wellington Management Group LLP now owns 136,289 shares of the biopharmaceutical company’s stock worth $1,138,000 after acquiring an additional 22,295 shares during the last quarter. State Street Corp increased its stake in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Stifel Financial Corp bought a new stake in Emergent BioSolutions during the 3rd quarter worth about $96,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Emergent BioSolutions in the 3rd quarter valued at about $1,547,000. Finally, Hilltop Holdings Inc. increased its position in shares of Emergent BioSolutions by 7.9% in the third quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 12,515 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on EBS shares. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday, December 28th. HC Wainwright began coverage on shares of Emergent BioSolutions in a research report on Monday, December 30th. They set a “buy” rating and a $15.00 price target on the stock. Benchmark boosted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Trading Up 0.5 %

EBS stock opened at $10.32 on Friday. Emergent BioSolutions Inc. has a one year low of $1.42 and a one year high of $15.10. The stock has a market cap of $559.18 million, a price-to-earnings ratio of -2.52 and a beta of 1.60. The company has a fifty day moving average price of $9.27 and a two-hundred day moving average price of $8.98. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.